MedPath

Septal closure of patent foramen ovale: does it prevent migraine?

Not Applicable
Completed
Conditions
Migraine, foramen ovale persistens, closure
Nervous System Diseases
Episodic and paroxysmal disorders
Registration Number
ISRCTN54702843
Lead Sponsor
St Jude Medical Inc (Belgium)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
50
Inclusion Criteria

1. Migraine with aura
2. Migraine history of at least one year:
a. at least two migraine attacks/month
b. at least one migraine attack with aura
3. Failure or intolerance to two classes prophylactic migraine medication
4. Aged 18 to 50 years
5. Right to left shunt suitable for closure

Exclusion Criteria

1. History of 15 or more headache days per month
2. Taking preventive medication for other conditions other than migraine
3. Eight or more non-migraine headache days/month
4. Overuse of acute headache medication (use on ten or more days/month)
5. Severe central nervous system disease
6. Previous surgical or device closure of Patent Foramen Ovale (PFO)/Atrial Septal Defect (ASD)
7. Atrial heart valve
8. Pacemaker or Implantable Cardioverter Defibrillator (ICD) implanted within past three months
9. History of atrial fibrillation
10. Undergoing dialysis
11. New York Heart Association (NYHA) class three or four cardiac failure
12. Pregnant
13. Anticoagulation

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<br> Number of patients experiencing 50% reduction of migraine in closure group compared with sham group.<br><br> Outcomes will be measured monthly from three to nine months after closure.<br>
Secondary Outcome Measures
NameTimeMethod
<br> 1. Mean values of monthly migraine periods<br> 2. Quality of Life (QoL) using headache impact test questionaire<br><br> Outcomes will be measured monthly from three to nine months after closure.<br>
© Copyright 2025. All Rights Reserved by MedPath